FGFR4 overexpression increases Bcl‐x expression through the MAPK cascade, implying that FGFR4 inhibitors combined with chemotherapeutic drugs could be useful for treating FGFR4‐overexpressing cancers [50]. The gene discussed is FGFR4; the disease is cancer.